Taking a patient-centric approach to treatment decisions ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌    Factors to consider when choosing RMS treatments in an ever-evolving landscape1,2 An expanding range of treatment options increases the complexity of decision-making1,3 With 15 DMTs currently available for the treatment of RMS, there are more therapeutic possibilities than ever before.1,2,4   Learn more about evolving considerations   Shared decision-making can help optimize each patient's unique treatment journey1,2   Ensuring adequate efficacy and understanding safety for the current stage of disease5   In the case of inadequate treatment response, transitioning to a DMT with a different proposed MOA may be appropriate2,5     The time needed for systemic clearance3,6,7   Route of administration and dosing frequency5 Drs. Vollmer and Foley discuss the importance of a patient-centric approach to decision-making   Watch the discussion: A collaborative approach   RMS=relapsing multiple sclerosis; DMT=disease-modifying therapy; MOA=mechanism of action. References: 1. Pardo G, Jones DE. J Neurol. 2017;264(12):23‍51-2‍374. 2. Giovannoni G, Butzkueven H, Dhib-Jalbut S, et al. Mult Scler Relat Disord. 2016;9(suppl 1):S5-S48. 3. Wingerchuk DM, Carter JL. Mayo Clin Proc. 2014;89(2):225-240. 4. National Multiple Sclerosis Society. Medications. ht‍tps://ww‍w.natio‍nalmssoc‍iety.o‍rg/Trea‍ting-MS/Medi‍cations. Accessed Au‍gust 1‍6, 20‍18. 5. MS Coalition. The use of disease-modifying therapies in multiple sclerosis: principles and current evidence. A consensus paper by the Multiple Sclerosis Coalition. htt‍p:/‍/ww‍w.na‍tionalm‍ssociety.o‍rg/ge‍tmedia/5ca284‍d3-fc7c-4ba5-b005-a‍b537d495c‍3c/DMT_Co‍nsensus_MS_Coalition_color. Updated March 2017. Accessed Ju‍ly 1‍8, 20‍18. 6. Du Pasquier RA, Pinschewer DD, Merkler D. CNS Drugs. 2014;28(6):535-558. 7. da Costa BK, Sato DK. Arq Neuropsiquiatr. 2016;74(8):605-606. You have received this email because you agreed to receive communications from Biogen. If you prefer not to receive further messages from this sender, please click here to unsubscribe and confirm your request.   © 2018 Biogen. All rights reserved. 08/18 FCH-US-4222 225 Binney Street Cambridge, MA 02142 800-456-2255